STOCK TITAN

Mustang Bio Inc - MBIO STOCK NEWS

Welcome to our dedicated news page for Mustang Bio (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mustang Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mustang Bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.44%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
earnings
-
Mustang Bio Inc

Nasdaq:MBIO

MBIO Rankings

MBIO Stock Data

10.81M
6.43M
22.77%
11.17%
3.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About MBIO

mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.